Longaeva Partners »

Summit Therapeutics shares owned by Longaeva Partners

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by Longaeva Partners from 13F filings

Historical chart of Longaeva Partners investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by Longaeva Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by Longaeva Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.1M 57k 18.96

More positions owned by Longaeva Partners

Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Boston Scientific Corporation Call Option (BSX)
Bank of America Corporation (BAC)
NVIDIA Corporation Call Option (NVDA)
PNC Financial Services (PNC)
Key (KEY)
Goldman Sachs (GS)
Morgan Stanley Com New (MS)
Minimed Group
Citizens Financial (CFG)
Evercore Class A (EVR)
Mastercard Incorporated Cl A (MA)
Msci (MSCI)
S&p Global (SPGI)
Us Bancorp Com New (USB)

View all positions for Longaeva Partners

Top funds holding Summit Therapeutics

Baker Bros. Advisors
FMR
Vanguard Group
BlackRock
State Street Corporation
Vanguard Capital Management
Vanguard Portfolio Management
UBS Group
Geode Capital Management
Susquehanna International
D. E. Shaw & Co
Morgan Stanley
Pictet Asset Management Holding SA
Apeiron Capital
Citadel Advisors

View all funds holding Summit Therapeutics